Yamashita, Y., Hori, Y., Kosako, H., Oiwa, T., Warigaya, K., Mushino, T., . . . Tamura, S. (2020). Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em> overexpression. MDPI AG.
Chicago Style (17th ed.) CitationYamashita, Yusuke, et al. Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-negative Anaplastic Large Cell Lymphoma in Leukemic Phase with <em>RUNX3</em> Overexpression. MDPI AG, 2020.
MLA (9th ed.) CitationYamashita, Yusuke, et al. Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-negative Anaplastic Large Cell Lymphoma in Leukemic Phase with <em>RUNX3</em> Overexpression. MDPI AG, 2020.
Warning: These citations may not always be 100% accurate.